Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $19.75.

Several brokerages have recently issued reports on MSLE. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a report on Friday, August 7th. Wells Fargo & Company set a $18.00 price target on shares of Satellos Bioscience in a report on Thursday, July 9th. Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Satellos Bioscience in a report on Monday, August 17th.

Satellos Bioscience Stock Performance

Shares of NASDAQ:MSLE opened at $9.05 on Thursday. The company has a market cap of $192.04 million, a P/E ratio of -4.71 and a beta of 1.53. The stock’s 50-day moving average is $9.17 and its 200-day moving average is $8.28. Satellos Bioscience has a 52-week low of $5.30 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.18). As a group, equities analysts predict that Satellos Bioscience will post -2.08 EPS for the current year.

Hedge Funds Weigh In On Satellos Bioscience

A hedge fund recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC grew its position in Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 491,624 shares of the company’s stock after acquiring an additional 391,624 shares during the quarter. Satellos Bioscience accounts for about 0.0% of Stonepine Capital Management LLC’s holdings, making the stock its 16th largest position. Stonepine Capital Management LLC owned 2.36% of Satellos Bioscience worth $3,723,291 at the end of the most recent reporting period.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.